VANCOUVER, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the Stifel 2024 Virtual CNS Days event.
Company Fireside Chat Presentation Details:
|
| |
| Date: |
Tuesday, March 19, 2024 |
| |
|
| Time: |
12:30-12:55 PM Eastern Time |
| |
|
| Webcast: |
Register here |
| |
|
| Presenters: |
Sherry Aulin, Chief Financial Officer |
| |
Chris Von Seggern, Chief Commercial Officer |
| |
|
A live webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com
For Media:
Jodi Regts
Xenon Corporate Affairs
(604) 484-3353
media@xenon-pharma.com
Source: Xenon Pharmaceuticals Inc.